Moreover, other biomarker-based treatment combinations, such as TROP2-targeted (e.g., sacituzumab deruxtecan, datopotamab deruxtecan) or CEACAM5-targeted (e.g., tusamitamab ravtansine) antibody–drug conjugates (ADCs) in combination with ICIs, should be explored in large prospective clinical trials in the perioperative setting, as these ADCs now have an established role in subsequent-line advanced NSCLC with clinically meaningful outcomes [101,102,103]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.